Figure 2.

Flowchart of the study design and study participants. There were a total of 558 participants enrolled in the HALT-A study including 521 class 1 and 30 class 2A. Seven participants missing baseline htTKV records were excluded. Five class 2A patients without exophytic cysts were excluded. For the CKD stage analysis, 83 participants who died or were lost to follow-up (LTF) before reaching CKD end points were excluded, resulting in a total of 458 participants, including 23 class 2Ae participants, in the analysis. For the eGFR analysis, five participants whose eGFR was <60 at baseline were excluded, resulting in a total of 541 participants, including 25 class 2Ae participants, in the analysis.